Loop Diuretics in Chronic Kidney Disease

Pharmacological Differences Between Loop Diuretics in CKD

The American College of Cardiology recommends torsemide over furosemide and bumetanide due to its longer duration of action, once-daily dosing, and maintained efficacy independent of renal function in patients with chronic kidney disease (CKD) 1
Torsemide has a longer duration of action (12-16 hours) compared to furosemide's 6-8 hours and bumetanide's 4-6 hours in patients with CKD 1, 2
Furosemide is relatively short-acting, usually requiring at least twice-daily dosing in patients with CKD 3, 4
Bumetanide has a short duration of action (4-6 hours), potentially requiring multiple daily dosing in patients with CKD 2
The maximum total daily dose of bumetanide is 10 mg in patients with CKD 2

Loop diuretics are preferred over thiazide diuretics due to maintained efficacy at lower GFR levels in patients with CKD 1
In patients with underlying CKD (creatinine clearance <30 mL/min), loop diuretics are necessary for effective volume and blood pressure control 3, 4
Torsemide is recommended as the loop diuretic of choice due to its pharmacokinetic advantages in patients with CKD 1
KDIGO guidelines recommend using longer-acting loop diuretics such as bumetanide or torsemide if concerned about treatment failure with furosemide in patients with CKD 5
For resistant edema, consider combination therapy with thiazide-like diuretics for synergistic effects in patients with CKD 5

For torsemide, initial dosing of 10-20 mg once daily is recommended, with titration based on response in patients with CKD 1
For bumetanide, initial dosing of 0.5 to 1.0 mg once or twice daily is recommended, with careful titration in patients with CKD 2

Monitor for adverse effects of diuretics, including hypokalemia, hyponatremia, impaired GFR, and volume depletion in patients with CKD 5
Do not stop ACEi or ARB with modest and stable increase in serum creatinine (up to 30%) when used concurrently with diuretics in patients with CKD 5
For diuretic-resistant patients, consider combination therapy or alternative strategies in patients with CKD 5